Back |
home / stock / aldr / aldr message board
Subject | By | Source | When |
---|---|---|---|
Dip @ $ALDR | Investor100 | investorshub | 07/18/2015 5:36:31 PM |
Upward @ $ALDR | Investor100 | investorshub | 07/16/2015 10:58:19 PM |
Steady @ $ALDR | Investor100 | investorshub | 07/11/2015 3:23:09 AM |
Added @ $ALDR | Investor100 | investorshub | 07/10/2015 1:20:45 AM |
Steady @ $ALDR | Investor100 | investorshub | 07/04/2015 6:27:51 PM |
Zacks @ $ALDR | Investor100 | investorshub | 07/02/2015 5:07:46 PM |
Stockcharts @ $ALDR | Investor100 | investorshub | 07/02/2015 5:05:43 PM |
Upward @ $ALDR | Investor100 | investorshub | 06/30/2015 10:33:24 PM |
Stock Issue @ $ALDR | Investor100 | investorshub | 06/30/2015 12:36:36 AM |
Stockcharts @ $ALDR | Investor100 | investorshub | 06/30/2015 12:31:08 AM |
Added @ $ALDR | Investor100 | investorshub | 06/25/2015 9:53:47 PM |
Upward @ $ALDR | Investor100 | investorshub | 06/25/2015 1:11:00 AM |
News, Short Squeeze, Breakout and More Instantly...
Alder BioPharmaceuticals Inc. Company Name:
ALDR Stock Symbol:
NASDAQ Market:
Alder BioPharmaceuticals Inc. Website:
Biotech is in the doldrums. The SPDR S&P Biotech ETF declined 18% in the past six months, and money continues to flow out of the sector. While several biotechs managed to IPO in September and October , it's not all roses. ADC Therapeutics pulled its plans to list citing market...
BOTHELL, Wash., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing therapeutic antibodies for the treatment of migraine, today announced dosing of the first patient in a Phase 1 clinical study to evaluate ALD191...
Shares of Alder Biopharmaceuticals (NASDAQ: ALDR) jumped 111% in September, according to data provided by S&P Global Market Intelligence , after the biotech said it will be acquired by Lundbeck. Lundbeck, a fairly large drugmaker in Denmark, is after Alder Pharmaceuticals' migraine m...